Monetary Management Group Inc. Has $41,000 Position in Danaher Corporation $DHR

Monetary Management Group Inc. lowered its stake in shares of Danaher Corporation (NYSE:DHR) by 78.9% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 200 shares of the conglomerate’s stock after selling 750 shares during the period. Monetary Management Group Inc.’s holdings in Danaher were worth $41,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of DHR. Heck Capital Advisors LLC purchased a new position in Danaher in the fourth quarter valued at about $27,000. GHP Investment Advisors Inc. lifted its holdings in shares of Danaher by 396.0% during the 1st quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate’s stock valued at $25,000 after buying an additional 99 shares during the last quarter. Sierra Ocean LLC grew its stake in shares of Danaher by 116.9% in the 1st quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate’s stock valued at $29,000 after buying an additional 76 shares in the last quarter. Smallwood Wealth Investment Management LLC acquired a new position in Danaher in the first quarter worth approximately $31,000. Finally, Dunhill Financial LLC increased its holdings in Danaher by 68.4% in the first quarter. Dunhill Financial LLC now owns 165 shares of the conglomerate’s stock worth $34,000 after buying an additional 67 shares during the last quarter. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Danaher Stock Performance

Shares of NYSE DHR opened at $211.7060 on Friday. Danaher Corporation has a 12 month low of $171.00 and a 12 month high of $279.90. The company has a market cap of $151.59 billion, a P/E ratio of 45.04, a P/E/G ratio of 2.85 and a beta of 0.73. The business’s 50 day moving average is $200.67 and its two-hundred day moving average is $199.53. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The business had revenue of $5.94 billion for the quarter, compared to the consensus estimate of $5.83 billion. During the same quarter last year, the company posted $1.72 earnings per share. Danaher’s quarterly revenue was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, equities analysts expect that Danaher Corporation will post 7.63 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. Guggenheim reissued a “buy” rating and issued a $250.00 target price on shares of Danaher in a research report on Wednesday, July 23rd. Wells Fargo & Company reduced their price objective on shares of Danaher from $210.00 to $205.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 23rd. Scotiabank raised shares of Danaher from a “sector perform” rating to a “sector outperform” rating and set a $275.00 target price on the stock in a research report on Friday, July 11th. Evercore ISI cut their target price on Danaher from $230.00 to $226.00 and set an “outperform” rating on the stock in a report on Tuesday, July 8th. Finally, Deutsche Bank Aktiengesellschaft reduced their price target on Danaher from $240.00 to $235.00 in a research report on Thursday, June 5th. Seventeen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $247.61.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.